Nanobiotix Raises $11M in Series C Financing Round

Nanobiotix, a Paris, France-based company wich develops innovative therapeutic products for cancer using nanotechnologies, closed a $11m Series C financing round.
The round was led by CIC Vizille Capital Innovation, with participation from Masseran Gestion, Matignon Technologies, OTC Asset Management, Cap Decisif Management, and Amorçage Rhône-Alpes.
This financing will enable the company to continue to advance its lead programs through clinical studies.

Nanobiotix plans to reinforce its scientific and development team and resources and is entering its first-in-man clinical study of nanoXray therapeutics with IGR Institut Gustave Roussy, a Europe leading cancer treatment center, for Soft Tissue Sarcoma as initial indication.
In parallel to the ongoing clinical developments, the company has also built an industrial and academic collaborative projects portfolio including research programs and industrial partnering, like Sonodrug with Philips Research or Biotech Corp in Malaysia.

Join the discussion